Table 2.
Signal detection for GLP-1 RAs-associated gastrointestinal adverse events.
| GLP-1 RA | The report number | ROR (95% CI) | PRR (χ2) | IC (IC025) | EBGM (EBGM05) |
|---|---|---|---|---|---|
| All GLP-1 RAs | 2,1281 | 1.46 (1.44 to 1.49) | 1.33 (2212.74) | 0.41 (0.38) | 1.33 (1.31) |
| Exenatide | 1,956 | 0.57 (0.54 to 0.60) | 0.63 (557.18) | −0.68 (-0.75) | 0.63 (0.60) |
| Liraglutide | 2,819 | 2.39 (2.28 to 2.51) | 1.84 (1383.55) | 0.88 (0.81) | 1.84 (1.76) |
| Dulagutide | 10,757 | 1.39 (1.36 to 1.42) | 1.28 (843.37) | 0.36 (0.32) | 1.28 (1.25) |
| Lixisenatide | 182 | 0.51 (0.44 to 0.60) | 0.57 (74.96) | −0.81 (−1.04) | 0.57 (0.49) |
| Semaglutide | 5,567 | 3.00 (2.89 to 3.11) | 2.10 (4082.54) | 1.07 (1.02) | 2.10 (2.03) |
PRR, the proportional reporting ratio; ROR, the reporting odds ratio; IC, the information component; EBGM, the empirical Bayes geometric mean; CI, confidence interval; 95% CI, two‐sided for ROR, χ2, chi-squared; IC025 and EBGM05 lower one‐sided for IC and EBGM.